采用超临界抗溶剂法制备吲哚美辛-羟丙基-β-环糊精复合微球.在单因素试验的基础上设计正交试验优选吲哚美辛-羟丙基-β-环糊精微球的制备工艺, 并考察其体外溶出度.在最优工艺条件下吲哚美辛-羟丙基-β-环糊精复合微球的平均载药量为66. 04％.扫描电镜所得结果表明所制得的吲哚美辛复合微球为不规则絮状.傅里叶红外吸收光谱和差示扫描量热表明所制得的吲哚美辛与羟丙基-β-环糊精形成了复合结构.溶出实验表明产吲哚美辛复合微球达到平衡的时间相较于其原料有很大延缓, 从而在保证药物溶出的前提下具备缓释效应.%Indometacin- (2-hydroxypropyl) -beta-cyclodextrin microspherewas prepared by supercritical CO2 anti-solvent technology. The preparation process was optimized basedon single factor experiments, and dissolution rate was investigated in vitro. Underthe optimum condition, drug loading of Indometacin- (2-hydroxypropyl) -beta-cyclodextrin microsphere was 66. 04％. The results of scanning electron microscopy showed that indomethacin composite microspheres were irregular flocculation. Fourier infrared absorption spectra and differential scanning calorimetryalso showed that the indomethacin and the carrier were formed. Dissolution experiments showed that the equilibrium time of indomethacin composite microspheres is much slower than that of raw materials, which making indomethacin drug had a certain slow-releasing effect.
展开▼
